A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1)

Share :
Published: 9 Oct 2016
Views: 1949
Dr Arndt Stahler - University of Munich, Munich, Germany

Dr Stahler speaks with ecancer at ESMO 2016 about his research targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) 3 cell lines, with expression levels have a potentially predictive value for patient response.

He summarises the results in cell lines and how this has translated to predicted and actual patient response.

Dr Stahler notes that this was an exploratory trial, and considers avenues of further upcoming validation trials.